Overview
- The peer-reviewed study published Wednesday in PNAS reports that optimized combinations of FETUA proteins were about ten times more potent than a commercial sheep-derived rattlesnake antivenom and fully neutralized rattlesnake lethality in laboratory tests.
- FETUA proteins are molecules in viper blood that evolved to block venom; the team found no single FETUA prevented death but that specific mixes greatly increased toxin neutralization.
- The July work built on a 2022 finding of a single blocker called FETUA-3 and focused on metalloproteinase toxins while researchers now apply the same approach to the other major viper toxin families.
- Authors outline a translational path that starts with recombinant, lab-made production and veterinary trials before human testing, noting that clinical development, regulatory review, and large-scale manufacturing remain to be completed.
- The research addresses limits of current antivenoms—which are made by immunizing horses or sheep, can be costly, species-limited, and trigger immune reactions—and could eventually expand access to safer, cheaper treatments for snakebite-affected rural communities.